UCB Group has hit the acquisition trial to snap up Engage Therapeutics of the US for an upfront payment of $125m, boosting its already strong presence in the epilepsy space.
UCB Acquires Engage To Boost Epilepsy Franchise
Paying $125m Upfront
The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which can rapidly terminate an epileptic seizure 30 seconds after it has begun.
